These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 17332295)

  • 1. Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients.
    Hansson L; Abdalla AO; Moshfegh A; Choudhury A; Rabbani H; Nilsson B; Osterborg A; Mellstedt H
    Clin Cancer Res; 2007 Mar; 13(5):1503-10. PubMed ID: 17332295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effects of idiotype vaccination on the specific T-cell response in peripheral blood and bone marrow of multiple myeloma patients.
    Abdalla AO; Hansson L; Eriksson I; Näsman-Glaser B; Mellstedt H; Osterborg A
    Eur J Haematol; 2007 Nov; 79(5):371-81. PubMed ID: 17916084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active idiotype vaccination in multiple myeloma. GM-CSF may be an important adjuvant cytokine.
    Mellstedt H; Osterborg A
    Pathol Biol (Paris); 1999 Feb; 47(2):211-5. PubMed ID: 10192891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early recovery of aggressive cytotoxic cells and improved immune resurgence with post-transplant immunotherapy for multiple myeloma.
    Meehan KR; Wu J; Bengtson E; Hill J; Ely P; Szczepiorkowski Z; Kendall M; Ernstoff MS
    Bone Marrow Transplant; 2007 Jun; 39(11):695-703. PubMed ID: 17417660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
    Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ
    Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine.
    Block MS; Suman VJ; Nevala WK; Kottschade LA; Creagan ET; Kaur JS; Quevedo JF; McWilliams RR; Markovic SN
    Melanoma Res; 2011 Oct; 21(5):438-45. PubMed ID: 21697748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
    Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
    Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells.
    Rasmussen T; Hansson L; Osterborg A; Johnsen HE; Mellstedt H
    Blood; 2003 Jun; 101(11):4607-10. PubMed ID: 12576327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.
    Bertinetti C; Zirlik K; Heining-Mikesch K; Ihorst G; Dierbach H; Waller CF; Veelken H
    Cancer Res; 2006 Apr; 66(8):4496-502. PubMed ID: 16618777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idiotype vaccination strategies in myeloma: how to overcome a dysfunctional immune system.
    Rhee Fv
    Clin Cancer Res; 2007 Mar; 13(5):1353-5. PubMed ID: 17332275
    [No Abstract]   [Full Text] [Related]  

  • 11. Antitumoral vaccination with granulocyte-macrophage colony-stimulating factor or interleukin-12-expressing DHD/K12 colon adenocarcinoma cells.
    Lechanteur C; Moutschen M; Princen F; Lopez M; Franzen E; Gielen J; Bours V; Merville MP
    Cancer Gene Ther; 2000 May; 7(5):676-82. PubMed ID: 10830715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological effects of granulocyte-macrophage colony-stimulating factor and autologous tumor vaccine in patients with renal cell carcinoma.
    Schwaab T; Tretter C; Gibson JJ; Cole BF; Schned AR; Harris R; Wallen EM; Fisher JL; Waugh MG; Truman D; Stempkowski LM; Crosby NA; Heaney J; Ernstoff MS
    J Urol; 2004 Mar; 171(3):1036-42. PubMed ID: 14767265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idiotype vaccination in patients with myeloma reduced circulating myeloma cells (CMC).
    Abdalla AO; Kokhaei P; Hansson L; Mellstedt H; Osterborg A
    Ann Oncol; 2008 Jun; 19(6):1172-9. PubMed ID: 18272909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential immunostimulating effect of granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF) and interferon gamma (IFNgamma) after severe trauma.
    Lendemans S; Kreuzfelder E; Waydhas C; Schade FU; Flohé S
    Inflamm Res; 2007 Jan; 56(1):38-44. PubMed ID: 17334669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
    Indrová M; Bubeník J; Mikysková R; Mendoza L; Símová J; Bieblová J; Jandlová T; Jinoch P; Smahel M; Vonka V; Pajtasz-Piasecka E
    Int J Oncol; 2003 Mar; 22(3):691-5. PubMed ID: 12579325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idiotype immunity (natural and vaccine-induced) in early stage multiple myeloma.
    Osterborg A; Henriksson L; Mellstedt H
    Acta Oncol; 2000; 39(7):797-800. PubMed ID: 11145435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor.
    Chen TT; Tao MH; Levy R
    J Immunol; 1994 Nov; 153(10):4775-87. PubMed ID: 7525715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.
    Soiffer R; Hodi FS; Haluska F; Jung K; Gillessen S; Singer S; Tanabe K; Duda R; Mentzer S; Jaklitsch M; Bueno R; Clift S; Hardy S; Neuberg D; Mulligan R; Webb I; Mihm M; Dranoff G
    J Clin Oncol; 2003 Sep; 21(17):3343-50. PubMed ID: 12947071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic effects of idiotype vaccination can be enhanced by the combination of granulocyte-macrophage colony-stimulating factor and interleukin 2 in a myeloma model.
    Stritzke J; Zunkel T; Steinmann J; Schmitz N; Uharek L; Zeis M
    Br J Haematol; 2003 Jan; 120(1):27-35. PubMed ID: 12492573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells.
    Reichardt VL; Milazzo C; Brugger W; Einsele H; Kanz L; Brossart P
    Haematologica; 2003 Oct; 88(10):1139-49. PubMed ID: 14555310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.